Month April 2020

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=”” type=”legacy”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes”…

As more trials take place and new emerging therapies are publicised, drug companies will now be under pressure to show their own compassion regarding drug development royalties. Moreover, in a time of economic regression and global health fears due to…

Some companies are repurposing or developing treatment, others are focusing on vaccines, tests or technology to deliver drugs in the body. Existing drugs being repurposed Gilead Sciences Inc’s (NASDAQ:GILD) antiviral medication remdesivir is undergoing the final phase of clinical trials,…